Feed MRNA
MR

Moderna

MRNA · NASDAQ

$182.56 +8.29% (+$13.98)
1M +24.52%
Market Cap $68.6B
P/E Ratio -
Div. Yield -
ROE 39.21%
Piotroski F-Score Weak
2/9
Valuation
0 /100
Expensive
P/B 10.15x
P/S 30.80x
PEG N/A
Growth
0 /100
Declining
Book val. growth 23.24%
Rev. growth 53.13%
FCF growth N/A
Profitability
0 /100
Weak
FCF margin 54.89%
Op. margin 149.01%
Gross margin 12.57%
Quality
3 /100
Poor
Asset turnover 0.20x
ROA 28.75%
ROIC 39.97%
Debt
69 /100
Low
Current ratio 2.29x
Int. coverage -122.80x
Debt/Equity 0.19x
Stability
50 /100
Moderate
Profitable years 0
EPS volatility 106.63%
Beta 0.90x

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o MRNA
Online

O podjetju

Moderna (MRNA) is a biopharmaceutical company specializing in the development of innovative drugs and vaccines. Their primary focus is on mRNA technology, which enables the creation of therapeutic and preventive products with high efficacy and safety. Moderna gained significant attention for its development of a COVID-19 vaccine, which has been approved and successfully deployed worldwide. Moderna stock is suitable for investors interested in the biotechnology sector and seeking opportunities in the field of therapeutic innovations and vaccines. Add Moderna stock to your watchlist on Bulios and be the first to receive updates on new developments, medical breakthroughs, and vaccines from this prominent company.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Stéphane Bancel

Employees

4,700

Headquarters

Cambridge

Prihajajoči dogodki

05 NOV.

Earnings

Upcoming earnings report

44d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.